Merck KGaA Signs a License Agreement with Y-Trap to Develop Antibody-Ligand Traps for Immuno-Oncology

 Merck KGaA Signs a License Agreement with Y-Trap to Develop Antibody-Ligand Traps for Immuno-Oncology

Merck KGaA Signs a License Agreement with Y-Trap to Develop Antibody-Ligand Traps for Immuno-Oncology

Shots:

  • Y-Trap to receive up front, pre/clinical development, regulatory & commercial milestones with royalties on sales. Merck KGaA & Y-Trap will explore pharmacology of Y-Trap multifunctional proteins while Merck will be responsible for development, manufacturing and commercialization activities
  • The collaboration involves Y-Trap’s platform of multifunctional antibody-ligand traps for immuno-oncology and Merck KGaA’s expertise in the research and development of bi-functional antibodies and proteins
  • The Y-Trap platform exploits combinatorial protein engineering countering key determinants of immune dysfunction in the tumor microenvironment. The antibody-ligand traps have an ability to unleash potent antitumor immune responses offering an immunotherapeutic strategy for advanced/refractory cancer indications

Click here to­ read full press release/ article | Ref: PRNewswire | Image: PRWeek

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post